- Home
- ACRE vs XOMA Comparison
ACRE vs XOMA Comparison
Compare ACRE & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRE
- XOMA
- Stock Information
- Founded
- ACRE 2011
- XOMA 1981
- Country
- ACRE United States
- XOMA United States
- Employees
- ACRE N/A
- XOMA N/A
- Industry
- ACRE Real Estate Investment Trusts
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- ACRE Real Estate
- XOMA Health Care
- Exchange
- ACRE Nasdaq
- XOMA Nasdaq
- Market Cap
- ACRE 278.1M
- XOMA 319.3M
- IPO Year
- ACRE 2012
- XOMA N/A
- Fundamental
- Price
- ACRE $4.96
- XOMA $23.52
- Analyst Decision
- ACRE Hold
- XOMA Strong Buy
- Analyst Count
- ACRE 8
- XOMA 2
- Target Price
- ACRE $6.60
- XOMA $72.00
- AVG Volume (30 Days)
- ACRE 746.6K
- XOMA 58.5K
- Earning Date
- ACRE 02-12-2025
- XOMA 03-07-2025
- Dividend Yield
- ACRE 18.14%
- XOMA N/A
- EPS Growth
- ACRE N/A
- XOMA N/A
- EPS
- ACRE N/A
- XOMA N/A
- Revenue
- ACRE $87,802,000.00
- XOMA $21,606,000.00
- Revenue This Year
- ACRE N/A
- XOMA $511.37
- Revenue Next Year
- ACRE $8.58
- XOMA $26.92
- P/E Ratio
- ACRE N/A
- XOMA N/A
- Revenue Growth
- ACRE 7874.75
- XOMA 389.82
- 52 Week Low
- ACRE $4.88
- XOMA $21.27
- 52 Week High
- ACRE $7.99
- XOMA $35.00
- Technical
- Relative Strength Index (RSI)
- ACRE 29.49
- XOMA 33.53
- Support Level
- ACRE $4.91
- XOMA $24.01
- Resistance Level
- ACRE $5.15
- XOMA $27.43
- Average True Range (ATR)
- ACRE 0.19
- XOMA 1.15
- MACD
- ACRE -0.07
- XOMA -0.22
- Stochastic Oscillator
- ACRE 6.53
- XOMA 0.00
About ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a Real Estate Investment Trust providing commercial real estate loans and related investments. It operates in one segment namely originating and managing a diversified portfolio of CRE debt-related investments. The group recognizes its revenues through the interest income it receives from loans.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.